MedTech Strategist Issue: Vol. 5, No. 5 - April 20, 2018
Already a Subscriber?
Not a Subscriber?
"Finding Meaningful Value in Medtech: An Interview with J&J’s Alex Gorsky, Part 2"
By David Cassak, Co-Editor-in-Chief
As Johnson & Johnson looks ahead, the healthcare giant sees tremendous opportunities in its core clinical spaces and a transformative role for high tech, as joint ventures with IBM and Verily attest. Medtech remains important, says CEO Alex Gorsky, because a diverse portfolio has helped J&J weather ups and downs in its different businesses over its 132-year history.
"Navigating New Technologies through Seismic Shifts: Medtech Execs, Investors Weigh In"
By Wendy Diller, Senior Writer/Market Analyst
Technological advances and Big Data capabilities, supported by robust financial valuations, are opening opportunities for successful medtech innovation, but long-term, ongoing market pressures require players to tailor value propositions to sophisticated strategies. Our roundtable of experts agrees that marshalled properly, digital health is a powerful tool that companies can leverage to their competitive advantage.
Start-Ups To Watch - "Neuspera Medical: Least Invasive Platform Increases Attractiveness of Neurostimulation"
By Mary Stuart, Senior Writer/Market Analyst
Current neuromodulation systems that are approved for chronic pain, overactive bladder and other conditions require surgical implantation, have bulky components under the surface of a patient’s skin, electronic leads that are prone to migration, and a limited battery life. Neuspera tackles these disadvantages and more with a wireless, mid-field powering method that requires only a tiny implant, inserted through a small puncture.
Start-Ups to Watch - "OneProjects’ VERAFEYE: Improving First-Procedure AF Ablation Success Rates"
By Mary Stuart, Senior Writer/Market Analyst
Success rates for first cardiac ablation procedures for atrial fibrillation, at just 50-60%, are surprisingly low in this well-developed medical sector, partly because today’s measurements rely on surrogates for success such as contact force, temperature, power, and time of ablation. OneProjects aims to providethe first catheter to deliver direct, 3D, intraprocedural analysis of the success of cardiac ablation, increasing the safety profile of ablation procedures and reducing costs to the healthcare system.
Technologies to Watch in 2018, Part 2
By MedTech Strategist's Editorial Team
We continue our exploration of technologies worth watching, focusing on advances in diabetes and surgical robotics, new treatment guidelines for ischemic stroke, minimally invasive spine surgery devices, and initiatives to expand neurostim into new pain markets.
Technologies to Watch in 2018, Part 2 - "Diabetes Devices: The High-Tech Transformation Continues"
By Mary Thompson, Executive Editor
The diabetes device market is one of the most dynamic growth opportunities in medtech, with a full pipeline of innovative products and an improving regulatory and payor landscape. But it is also fast moving and fiercely competitive, and the next few years could determine many winners and losers in this space.
Technologies to Watch 2018, Part 2 - "Surgical Robotics: The Future is Now"
By David Cassak, Co-Editor-in-Chief
What started as a trickle slightly more than two decades ago is now a deluge. Is there a hotter topic in medtech right now than robotics?
Technologies to Watch in 2018, Part 2 - "Bioresorbable Stents: Coatings Take Center Stage, Scaffolds a Back Seat"
By Stephen Levin, Co-Editor-in-Chief
Fully bioresorbable stents were presumed by many to be the next major device blockbuster in cardiology. But disappointing initial results have tempered this early optimism, reviving interest and opportunities in stents with bioresorbable coatings, previously viewed almost as an afterthought.
Technologies to Watch in 2018, Part 2 - "New Data and More Expansive Guidelines Give Ischemic Stroke Market a Push"
By Mary Thompson, Executive Editor
The market for ischemic stroke devices—including clot retrievers and aspiration systems—got a boost earlier this year with the release of compelling new clinical data favoring the use of endovascular therapy well beyond the established six-hour treatment window. The findings prompted the rapid release of revised treatment guidelines that push eligibility out as far as 24 hours after last-known well, a change that could open up endovascular therapy to as many as 100,000 or more patients per year in the US. While logistical issues remain to be worked out, device competitors are adding to their product portfolios in preparation for increased demand ahead, and newcomers are on the horizon.
Technologies to Watch in 2018, Part 2 - "MIS Spine: Advances in Visualization, Navigation, and Robotics"
By Wendy Diller, Senior Writer/Market Analyst
Minimally invasive surgery has been slow to take off in spine compared with other surgical specialties, but growing comfort with robotics and navigation systems and new, easier to use devices mean a jump up on the evolutionary scale.
Technologies to Watch in 2018, Part 2 - "Start-Ups Expand Device Markets for Pain with Peripheral Nerve Stimulation and Less Invasive Platforms"
By Mary Stuart, Senior Writer/Market Analyst
Start-ups are revamping neurostimulation platforms for pain to address the 90% of patients eligible for spinal cord stimulation who aren’t opting for it, and to expand the market to patients with isolated pain originating in peripheral nerves. In order to create device therapies with the potential to come in as front-line alternatives to opioids, companies are miniaturizing implants and offering outpatient procedures.
Not a Subscriber?
Already a Subscriber?
Want a Sample?
Companies covered in this issue: Abbott Laboratories, Abbott Vascular, AgaMatrix Holdings LLC, Auris Surgical Robotics, Bayer Healthcare, Bigfoot Biomedical, Bioness Inc., Biosensors, Biotronik, BlueWind Medical Ltd., Boston Scientific Corp., Brainlab AG, Cardinal Health, Cerebrotech Medical Systems, Corindus Vascular Robotics, Curexo, DePuy, DexCom, Eli Lilly, Galen Robotics, Globus Medical Inc., Hansen Medical, IBM Watson Health, Intuitive Surgical, iSense CGM Inc., Insulet Corp., iSchemaView Inc. ,K2M Group Holdings Inc., Lepu, Mazor Robotics Ltd., Micell, MicroPort, MMI, Neuros Medical Inc., Neuspera Medical Inc., NuVasive Inc., Omni, OrbusNeich, Penumbra Inc., Preceyes BV, Renew Spine Care Inc., Roche, Senseonics Holdings, Smith & Nephew, SPR Therapeutics, StimRelieve, Stimwave LLC, Stryker Corp., Tandem Diabetes Care, Terumo, TransEnterix, TypeZero Technologies, Verb Surgical, Vericel Corp., Verily Life Sciences, Wenzel Spine, Zimmer/Biomet, Johnson & Johnson, Bioventus, Entellus Medical, iRhythm Technologies, Magnolia Medical, MedoveX Corp., Medtronic plc, LivaNova plc, Neuspera Medical Inc., Stanford University, OneProjects, Securus Medical Group
Topics covered in this issue: Cardiovascular; Vascular; Orthopedics; Spine; Business Strategies & Development; Ophthalmology; Surgery/Minimally Invasive Surgery/Robotics; Executive Interviews; Digital Health; Health Information Technology; Investment/Finance/M&As; Diabetes; Neurostimulation/Neuromodulation; Pain Management; Imaging; Start-Ups
